BAM files and phenotype data available to all investigators through completion of a Data Access Procedures process in the St. Jude Cloud.
The table below provides characteristics for genome sequenced CCSS participants.
| Characteristic | CCSS Participants with Whole Exome Data (N=2641) | |
|---|---|---|
| N | % | |
| Sex | ||
| Male | 1240 | 47.5 |
| Female | 1401 | 52.5 |
| Ancestry (based on genotype) | ||
| European | 2114 | 78.8 |
| Non-European | 527 | 21.2 |
| Primary Cancer Diagnosis | ||
| Acute lymphoblastic leumeia | 452 | 35.1 |
| Acute myeloid leukemia | 77 | 2.3 |
| Other leukemia | 20 | 0.6 |
| Astrocytoma | 403 | 12.0 |
| Medulloblastoma/PNET | 167 | 5.0 |
| Other CNS malignancy | 104 | 3.1 |
| Hodgkin lymphoma | 311 | 9.2 |
| Non-Hodgkin lymphoma | 253 | 7.5 |
| Kidney tumor | 291 | 7.4 |
| Neuroblastoma | 256 | 7.6 |
| Soft tissue sarcoma | 138 | 4.1 |
| Ewong sarcoma | 90 | 2.7 |
| Osteosarcoma | 312 | 2.7 |
| Other bone malignancy | 20 | 0.6 |
| Age at Cancer Diagnosis | ||
| 0-4 yrs | 922 | 39.9 |
| 5-9 yrs | 626 | 25.9 |
| 10-14 yrs | 654 | 20.8 |
| 15-21 yrs | 439 | 13.4 |
| Year of Cancer Diagnosis | ||
| 1970 -1975 | 0 | |
| 1976-1981 | 0 | |
| 1982-1986 | 0 | |
| 1987-1991 | 974 | 37.0 |
| 1992-1995 | 856 | 33.4 |
| 1996-1999 | 811 | 29.6 |
| Radiotherapy for Primary Cancer | ||
| Yes | 1011 | 33.2 |
| No | 1535 | 63.3 |
| Unknown* | 95 | 3.5 |
| Chemotherapy for Primary Cancer | ||
| Yes | 2057 | 82.0 |
| No | 490 | 14.5 |
| Unknown* | 94 | 3.5 |
Percentages weighted to reflect modified sampling of all survivors in expansion cohort; WES, Whole Exome Sequencing; WGS, Whole Genome Sequencing.
*Participants did not provide consent for medical record.
#WES Data, Original Cohort, is a subset of the population with genotype data.